Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Metronomic Capecitabine in High Risk HER2+ Breast Cancer
NCT03561740Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2018
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Sun Yat-sen University. Started Jul 2018; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03561740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03561740.